Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 13,084 matching trials from the live ClinicalTrials.gov search.
Conditions
Chronic Kidney Disease, Congenital Anomalies of Kidney and Urinary Tract
Interventions
Renal Autologous Cell Therapy (REACT)
Biological
Lead sponsor
Prokidney
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Atlanta, Georgia • Meridian, Idaho • Neptune City, New Jersey + 2 more
Conditions
Major Depressive Disorder
Interventions
Brenipatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
35
States / cities
Phoenix, Arizona • Chino, California • Montclair, California + 28 more
Completed No phase listed Observational

3T MRI CIED Post-Approval Study

NCT02969395
Conditions
Cardiac Rhythm Disorder
Interventions
Not listed
Lead sponsor
Medtronic
Industry
Eligibility
Not listed
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
118
States / cities
Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 115 more
Conditions
Hyperactivity in Children With Down Syndrome, Impulsivity in Children With Down Syndrome
Interventions
Guanfacine Hydrochloride Immediate Release, Placebo
Drug
Lead sponsor
Rachel G. Greenberg, MD, MB, MHS
Other
Eligibility
6 Years to 12 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
14
States / cities
Phoenix, Arizona • Atlanta, Georgia • Chicago, Illinois + 11 more
Conditions
Cystic Fibrosis
Interventions
Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
2 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
12
States / cities
Birmingham, Alabama • Denver, Colorado • Atlanta, Georgia + 9 more
Conditions
Lung Cancer
Interventions
chromogenic in situ hybridization, gene expression analysis, mutation analysis, polymerase chain reaction, polymorphism analysis, fluorescent antibody technique, immunohistochemistry staining method, laboratory biomarker analysis, matrix-assisted laser desorption/ionization time of flight mass spectrometry, study of socioeconomic and demographic variables, study of high risk factors
Genetic · Other · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
981 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
405
States / cities
Anchorage, Alaska • Tucson, Arizona • Fort Smith, Arkansas + 279 more
Terminated Phase 3 Interventional Results available

Coenzyme Q10 in Huntington's Disease (HD)

NCT00608881
Conditions
Huntington's Disease
Interventions
coenzyme Q10, placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years and older
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
41
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 37 more
Conditions
Prostate Cancer
Interventions
WST 11 -mediated -VTP
Drug
Lead sponsor
Steba Biotech S.A.
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Los Angeles, California • Atlanta, Georgia • St Louis, Missouri + 1 more
Conditions
Crohn's Disease
Interventions
Certolizumab pegol, Placebo
Biological · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
31
States / cities
San Francisco, California • Gainesville, Florida • Atlanta, Georgia + 28 more
Conditions
Glioma, Astrocytoma, Grade IV, IDH1-mutant Glioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Astrocytoma, IDH-Mutant, Grade 2, Oligodendroglioma, Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted
Interventions
safusidenib, Placebo
Drug
Lead sponsor
Nuvation Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
49
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 39 more
Conditions
B-cell Acute Lymphoblastic Leukemia, Obesity
Interventions
IDEAL2 Intervention
Behavioral
Lead sponsor
Etan Orgel
Other
Eligibility
7 Years to 25 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
16
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 13 more
Completed No phase listed Observational

REBYOTA™ Prospective Registry

NCT05835219
Conditions
Recurrence of Clostridium Difficile Infection
Interventions
REBYOTA™
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
42
States / cities
Chandler, Arizona • Chula Vista, California • Murrieta, California + 36 more
Completed Phase 3 Interventional Results available

BOTOX® Treatment in Pediatric Lower Limb Spasticity

NCT01603628
Conditions
Pediatrics, Muscle Spasticity, Cerebral Palsy
Interventions
botulinum toxin Type A, Normal Saline (Placebo)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
2 Years to 16 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
24
States / cities
Pasadena, California • Pomona, California • Aurora, Colorado + 19 more
Conditions
Staphylococcal Infection
Interventions
Trimethoprim-sulfamethoxazole, Placebo, Clindamycin
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 85 Years
Enrollment
1,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
San Francisco, California • Torrance, California • Atlanta, Georgia + 3 more
Conditions
Hypertension, Portal
Interventions
GR-MD-02, Placebo
Drug
Lead sponsor
Galectin Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
46
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 39 more
Conditions
Heart Failure, Type 2 Diabetes Mellitus
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
94
States / cities
Alexander City, Alabama • Cottonwood, Arizona • Little Rock, Arkansas + 83 more
Conditions
Lupus Erythematosus, Systemic
Interventions
VIB7734, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
17
States / cities
Upland, California • Clearwater, Florida • Ormond Beach, Florida + 14 more
Conditions
Aortoiliac Occlusive Disease, Peripheral Arterial Disease
Interventions
Stenting of the Common and/or External Iliac Arteries with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis, Stenting of the Common and/or External Iliac Arteries with Bare Metal Stent
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
26
States / cities
Little Rock, Arkansas • Long Beach, California • Denver, Colorado + 20 more
Conditions
Ulcerative Colitis
Interventions
Placebo, Guselkumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,064 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
52
States / cities
Lancaster, California • Los Angeles, California • Colorado Springs, Colorado + 42 more
Conditions
HIV Infections
Interventions
Abacavir sulfate, Amprenavir, Efavirenz, Adefovir dipivoxil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
13 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Beverly Hills, California • Denver, Colorado • Atlanta, Georgia + 2 more
Conditions
Depression, Major Depressive Disorder, MDD, Insomnia
Interventions
suvorexant, Placebo
Drug
Lead sponsor
Institute for Advanced Medical Research, Alpharetta, GA
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Atlanta, Georgia • Augusta, Georgia
Conditions
Hip Fractures, Myocardial Injury
Interventions
Accelerated medical clearance and surgery
Other
Lead sponsor
Population Health Research Institute
Other
Eligibility
45 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Chandler, Arizona • Davis, California • Irvine, California + 19 more
Conditions
Plasma Cell Myeloma
Interventions
Belantamab Mafodotin, Dexamethasone, Pomalidomide
Biological · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Multiple Sclerosis
Interventions
Frexalimab, MRI contrast-enhancing preparations
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 60 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
34
States / cities
Cullman, Alabama • Homewood, Alabama • Phoenix, Arizona + 29 more